Beta-glucocerebrosidase
Beta-glucocerebrosidase Brand names, Beta-glucocerebrosidase Analogs
Beta-glucocerebrosidase Brand Names Mixture
- No information avaliable
Beta-glucocerebrosidase Chemical_Formula
C2532H3854N672O711S16
Beta-glucocerebrosidase RX_link
http://www.rxlist.com/cgi/generic2/imiglucerase.htm
Beta-glucocerebrosidase fda sheet
Beta-glucocerebrosidase msds (material safety sheet)
Beta-glucocerebrosidase Synthesis Reference
No information avaliable
Beta-glucocerebrosidase Molecular Weight
55597.4
Beta-glucocerebrosidase Melting Point
No information avaliable
Beta-glucocerebrosidase H2O Solubility
No information avaliable
Beta-glucocerebrosidase State
Liquid
Beta-glucocerebrosidase LogP
-0.168
Beta-glucocerebrosidase Dosage Forms
Powder for solution; Solution (IV injection)
Beta-glucocerebrosidase Indication
For the treatment of Gaucher's disease (deficiency in glucocerebrosidase)
Beta-glucocerebrosidase Pharmacology
Gaucher disease is characterized by a functional deficiency in Beta-glucocerebrosidase enzymatic activity and the resultant accumulation of lipid glucocerebroside in tissue macrophages which become engorged and are termed Gaucher cells. Gaucher cells are typically found in liver, spleen and bone marrow. This can lead to an enlarged spleen and liver (hepatosplenomegaly). Secondary hematologic sequelae include severe anemia and thrombocytopenia. Injections of imiglucerase into Gaucher disease patients leads to elevated serum levels of the enzyme and reduction in the accumulation of glucocerebroside leading to reduced anemia and thrombocytopenia, reduced spleen and liver size, and decreased cachexia
Beta-glucocerebrosidase Absorption
No information avaliable
Beta-glucocerebrosidase side effects and Toxicity
No information avaliable
Beta-glucocerebrosidase Patient Information
No information avaliable
Beta-glucocerebrosidase Organisms Affected
Humans and other mammals
